Profile data is unavailable for this security.
About the company
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
- Revenue in USD (TTM)0.00
- Net income in USD-215.79m
- Incorporated2017
- Employees331.00
- LocationReplimune Group Inc500 Unicorn Park DrWOBURN 01801-3377United StatesUSA
- Phone+1 (781) 222-9600
- Fax+1 (302) 655-5049
- Websitehttps://www.replimune.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ACELYRIN Inc | 0.00 | -240.16m | 679.33m | 130.00 | -- | 1.05 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
SS Innovations International Inc | 11.22m | -22.75m | 682.96m | 239.00 | -- | 50.46 | -- | 60.87 | -0.1372 | -0.1372 | 0.0698 | 0.0793 | 0.6146 | -- | 2.43 | 46,943.05 | -124.63 | -161.38 | -289.30 | -449.76 | 11.08 | -79.79 | -202.80 | -495.77 | 0.8699 | -57.41 | 0.3901 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
ORIC Pharmaceuticals Inc | 0.00 | -101.76m | 689.06m | 102.00 | -- | 2.10 | -- | -- | -1.81 | -1.81 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -35.25 | -33.92 | -37.18 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
Mineralys Therapeutics Inc | 0.00 | -90.80m | 689.62m | 28.00 | -- | 2.10 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 700.62m | 1.22k | -- | 0.6845 | -- | 3.36 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
IGM Biosciences Inc | 2.11m | -236.92m | 702.97m | 216.00 | -- | 4.35 | -- | 333.95 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
Phathom Pharmaceuticals Inc | 2.59m | -246.63m | 708.86m | 452.00 | -- | -- | -- | 273.27 | -4.41 | -4.41 | 0.047 | -2.54 | 0.0104 | -- | -- | 5,738.94 | -98.55 | -83.26 | -111.44 | -93.77 | 77.14 | -- | -9,507.71 | -135,982.00 | 7.80 | -5.29 | 1.46 | -- | -- | -- | -1.96 | -- | -- | -- |
Allogene Therapeutics Inc | 87.00k | -292.30m | 712.67m | 232.00 | -- | 1.26 | -- | 8,191.65 | -1.78 | -1.78 | 0.0005 | 2.71 | 0.0001 | -- | -- | 375.00 | -43.85 | -28.46 | -47.04 | -30.21 | -- | -- | -335,973.60 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Stoke Therapeutics Inc | 7.85m | -108.53m | 713.00m | 110.00 | -- | 4.53 | -- | 90.89 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
Replimune Group Inc | 0.00 | -215.79m | 713.10m | 331.00 | -- | 1.74 | -- | -- | -3.24 | -3.24 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -38.05 | -29.08 | -40.71 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1593 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
Arbutus Biopharma Corp | 12.99m | -74.39m | 713.35m | 73.00 | -- | 5.94 | -- | 54.93 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
Scholar Rock Holding Corp | 0.00 | -183.26m | 713.80m | 150.00 | -- | 3.90 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Zymeworks Inc | 50.46m | -125.97m | 715.53m | 275.00 | -- | 1.65 | -- | 14.18 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Wave Life Sciences Ltd | 112.91m | -61.67m | 723.83m | 266.00 | -- | 28.47 | -- | 6.41 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
SAGE Therapeutics Inc | 91.06m | -503.14m | 731.21m | 487.00 | -- | 1.04 | -- | 8.03 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Holder | Shares | % Held |
---|---|---|
Baker Bros. Advisors LPas of 31 Mar 2024 | 9.55m | 15.54% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 6.39m | 10.41% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.94m | 6.42% |
Redmile Group LLCas of 31 Mar 2024 | 3.73m | 6.07% |
Camber Capital Management LPas of 31 Mar 2024 | 2.75m | 4.48% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.70m | 4.40% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.54m | 4.14% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.19m | 1.94% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.16m | 1.89% |
Jefferies LLCas of 31 Mar 2024 | 1.00m | 1.63% |